Trial Profile
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Assessment of the Efficacy in Reduction of Nasal Polyp Size in Patients With Nasal Polyposis and Concomitant Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2022
Price :
$35
*
At a glance
- Drugs Fevipiprant (Primary) ; Mometasone
- Indications Asthma; Nasal polyps
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms THUNDER
- Sponsors Novartis Pharmaceuticals
- 27 Jan 2022 Primary endpoint (Change From Baseline in Nasal Polyp Score at Week 16) has not been met, as per results published in the Journal of Allergy and Clinical Immunology
- 27 Jan 2022 Results published in the Journal of Allergy and Clinical Immunology
- 14 Nov 2020 This trial is completed in Netherlands and Italy according to European Clinical Trials Database record.